Paclitaxel albumin is the same as albumin-bound paclitaxel, often referred to as paclitaxel albumin, and is used primarily for the treatment of metastatic breast cancer that has failed chemotherapy, among other things. Paclitaxel albumin is commonly available as an injection under the drug name Paclitaxel (albumin-bound) for Injection, and is suitable for patients with metastatic breast cancer who have failed combination chemotherapy, as well as for adjuvant treatment of breast cancer that has recurred within six months of chemotherapy, unless there are contraindications to the patient’s prior chemotherapy, which should include an anthracycline-based anticancer agent. Adverse reactions to this product include edema, ECG abnormalities, peripheral edema, alopecia, constipation, loss of appetite, anemia, thrombocytopenia, elevated alkaline phosphatase, arthralgia, visual disturbances, dehydration, fatigue, cardiac arrest, hypersensitivity, and pneumonia. The product is contraindicated in patients with baseline blood neutrophils less than 1500/ml and patients with severe allergy to the product. It is recommended that patients who are unwell go to regular hospitals in time, and follow the doctor’s instructions for symptomatic treatment with medication.